PLCε (phospholipase Cε) is a novel PLC that has a CDC25 guanine nucleotide exchange factor domain and two RA (Rasassociation) domains of which the second (RA2) is critical for Ras activation of the enzyme. In the present studies, we examined hormonal stimulation to elucidate receptor-mediated pathways that functionally regulate PLCε. We demonstrate that EGF (epidermal growth factor), a receptor tyrosine kinase agonist, and LPA (lysophosphatidic acid), S1P (sphingosine 1-phosphate) and thrombin, GPCR (G-protein-coupled receptor) agonists, stimulate PLCε overexpressed in COS-7 cells. EGF stimulated PLCε in an RA2-dependent manner through Ras and Rap. In contrast, LPA, S1P and thrombin stimulated PLCε by both RA2-independent and -dependent mechanisms. To determine the G-proteins that mediate the effects of these GPCR agonists, we co-expressed constitutively active G-proteins with PLCε and found that G α12 , G α13 , Rho, Rac and Ral stimulate PLCε in an RA2-independent manner; whereas TC21, Rap1A, Rap2A and Rap2B stimulate PLCε in an RA2-dependent manner similar to H-Ras. Of these G-proteins, we show that G α12 /G α13 and Rap partly mediate the effects of LPA, S1P and thrombin to stimulate PLCε. In addition, the stimulation by LPA and S1P is also partly sensitive to pertussis toxin. These studies demonstrate diverse hormonal regulation of PLCε by distinct and overlapping pathways.
INTRODUCTION
Phosphatidylinositide-specific PLC (phospholipase C) is a critical cellular enzyme that hydrolyses PtdIns(4,5)P 2 to generate InsP 3 and diacylglycerol, which stimulate Ca 2+ mobilization and protein kinase C respectively [1, 2] . Four main classes, which include several isoforms, have been identified based on structure and regulation: PLCβ1-4, PLCγ 1-2, PLCδ1-4 and PLCε. PLCβ is regulated by GPCRs (G-protein-coupled receptors) through G-proteins of the Gα q family and Gβγ subunits. PLCγ is regulated by receptor and non-receptor protein tyrosine kinases. The mechanism regulating PLCδ is unclear but possibly involves Ca 2+ and G h , high-molecular-mass G-protein.
The newest member of this group is PLCε, which, in addition to conserved PLC catalytic domains, has an N-terminal CDC25 GEF (CDC25 guanine nucleotide exchange factor) domain and two C-terminal Ras-binding RA (Ras-association) domains [3] [4] [5] . In addition to Ras [3, 6] , other G-proteins have been shown to stimulate PLCε including G α12 [4] , TC21 [7] , Gβγ [8] and Rap1A and Rap2B [6] . We have shown that the second RA domain (RA2) binds Ras by a typical Ras-effector interaction and that mutations in this domain inhibit binding of Ras and activation of PLCε in parallel, strongly suggesting direct regulation [3] . In contrast, the mechanism by which G α12 and Gβγ stimulate PLCε is not known, but, unlike Ras, Gβγ stimulation is not inhibited by mutations in the RA2 domain [8] .
EGF (epidermal growth factor) is a member of six EGF family hormones that are generated by the proteolytic cleavage of transmembrane precursors by metalloproteinases and are important mediators of proliferation and differentiation [9] . EGF binds the EGFR (EGF receptor; HER or ErbB), a RTK (receptor tyrosine Abbreviations used: GEF, guanine nucleotide exchange factor; PLC, phospholipase C; GPCR, G-protein-coupled receptor; RA, Ras-association; EGF, epidermal growth factor; EGFR, EGF receptor; RTK, receptor tyrosine kinase; LPA, lysophosphatidic acid; S1P, sphingosine 1-phosphate; GST, glutathione S-transferase; FBS, fetal bovine serum; RGS, regulators of G-protein signalling. 1 To whom correspondence should be addressed (e-mail kelleyg@upstate.edu).
kinase), and induces homodimerization and/or heterodimerization with other ErbB family receptor members, which leads to activation and autophosphorylation of tyrosine residues that serve as docking sites for effector proteins. PLCγ 1 is one of these effectors that binds EGFR through its SH (Src homology) 2 domains and is phosphorylated at specific tyrosine residues that are necessary for its activation [10] . The Grb2-Sos complex also interacts with activated EGFR and activates Ras through the Ras GEF activity of Sos [11] . Similarly, EGFR interacts with Crk and the Rap GEF, C3G, to activate Rap1 and Rap2 [12] . In contrast to EGF, LPA (lysophosphatidic acid) [13] , S1P (sphingosine 1-phosphate) [14] and thrombin [15] activate heptahelical GPCRs and are important regulators of critical cellular functions including mitogenesis and anti-apoptosis. The phospholipids LPA and S1P bind and activate LPA 1−3 and S1P 1−5 (previously EDG 1−8 ) receptors and thrombin activates proteinaseactivated receptors, PAR 1, 3, 4 , by cleaving the N-terminus of the receptor and unmasking an activating ligand. This group of GPCRs couples to heterotrimeric G-proteins of the G i , G q and G 12 families. Agonist activation of these receptors has been shown to stimulate PLCβ isoforms through the Gα subunits of the G q family and Gβγ subunits liberated from activated G i /G o in a pertussis toxin-sensitive manner. Recently, these agonists have also been shown to been shown to transactivate the EGFR and activate the Ras/mitogen-activated protein kinase pathway [16, 17] .
In the present studies, we examined the hormonal regulation of PLCε by these diverse agonists. We demonstrate that these RTK and GPCR-coupled agonists stimulate PLCε by distinct pathways involving RA2-dependent and -independent mechanisms. EGF stimulates PLCε through Ras and/or a Ras-like GTPase in a completely RA2-dependent manner. Serum, LPA, S1P and thrombin, on the other hand, require an intact RA2 domain for complete stimulation but also stimulate in an RA2-independent manner through G α12 /G α13 and G i .
EXPERIMENTAL

Materials
Reagents used were EGF, S1P and pertussis toxin from Calbiochem (La Jolla, CA, U.S.A.); LPA from Sigma (St. Louis, MO, U.S.A.); and α-thrombin from Haematologic Technologies (Essex Junction, VT, U.S.A.). Antibodies used were anti-PLCγ 1 and anti-PLCβ1 from Upstate Biotechnologies (Lake Placid, NY, U.S.A.), anti-FLAG from Sigma, anti-Ras, anti-EGF receptor, anti-Rap1, anti-Rap2 and anti-RalA from BD Transduction Laboratories (Lexington, KY, U.S.A.), anti-HA from Roche Diagnostics (Manheim, Germany), and anti-PLCβ2, anti-G α12 and anti-G α13 from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-PLCε used in these studies was a rabbit polyclonal antibody generated to the RA1 domain.
GST (glutathione S-transferase) pull-down assay
A GST pull-down assay was performed as described previously [3] . Briefly, transformed DH5α Escherichia coli were induced with isopropyl β-D-thiogalactoside (400 µM) for 4 h at room temperature, except GST RBD Raf-1 (where RBD is Ras-binding domain) and pGEX vector for 2 h at 37
• C, and then pelleted and stored at − 70
• C for less than 1 month. GST fusion proteins were isolated using glutathione-Sepharose 4B (Amersham Biosciences, Piscataway, NJ, U.S.A.) according to the manufacturer's instructions and typically 250 pmol of fusion protein was then incubated for 2 h or overnight with 200-400 µg of a COS-7 cell lysate overexpressing the indicated G-proteins at 4 • C. Following four washes, Western blot analysis was performed using SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL, U.S.A.) for detection.
Transfection of COS-7 cells and PLC activity assay
COS-7 cells (ATCC, Manassas, VA, U.S.A.) were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % FBS (fetal bovine serum). PLC activity was determined as described previously [3] with the following modifications. Cells were routinely used at passages 20-30 unless indicated; lower-passage cells give higher basal PLCε activity. Cells were seeded into 24-well tissue-culture plates at a density of 4 × 10 5 , grown overnight and then transfected in conditioned medium with 0.25 µg of each type of cDNA construct (unless indicated otherwise) using 1 µl of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, U.S.A.) per well following the manufacturer's protocol. After exposure to the DNA-liposome complex overnight, the cells to be assayed for PLC activity were labelled for 24 h with 2 µCi of [
3 H]myoinositol in inositol-free, serum-free medium.
The PLC assay was initiated with the addition of reagents or vehicle where indicated and 20 mM LiCl, and incubated for 60 min unless indicated. Agonists were dissolved as follows: LPA, 0.1 % BSA in PBS; S1P, 100 % methanol; thrombin, 0.1 % poly-(ethylene glycol)/1 mg/ml BSA in PBS; and EGF, 0.1 % BSA/ 10 mM acetic acid. The reaction was stopped by aspirating off the incubation medium and adding 375 µl of ice-cold 50 mM formic acid. After a 15 min incubation on ice, samples were removed, neutralized with 125 µl of 150 mM NH 4 OH and diluted with 5 ml of ice-cold water. Total inositol phosphates were separated by column chromatography using AG 1-X8 200-400 µm mesh, formate form, and quantitated by liquid scintillation counting. Expression was determined in parallel wells without radioactivity by Western blot analysis and was not significantly different within an experiment unless stated. Steady-state labelling of PtdIns was not significantly different between conditions unless stated.
Calculations and statistical analysis
Experiments were performed in duplicate except EGF experiments with S17N H-Ras and RapGAP1, which were performed in quadruplicate. A LacZ control, in which a plasmid expressing LacZ replaces the variable being examined in the transfection, was determined for each condition. In some figures the data have been reduced for comparison purposes. Basal PLC activity attributable to a given PLC isoform was determined by subtracting the c.p.m. obtained for the LacZ control from the overexpressed PLC isoform c.p.m. and is given when a data tranformation is made, e.g. PLCε − LacZ. For stimulation, because the basal PLC activity was different for each PLC isoform and stimulation by EGF was less than the GPCR agonists, the measure fold basal PLC isoform was used. This was calculated by first subtracting the LacZ control for each condition and then dividing the stimulated by unstimulated c.p.m., e.g. (PLCεLPA − LacZLPA)/ (PLCε − LacZ). For inhibition, percentage of control stimulation was used. This was calculated by first subtracting the LacZ control for each condition, then subtracting the unstimulated PLC activity from the stimulated PLC activity and then dividing the c.p.m. obtained with the mutant PLCε or inhibitor by the counts without the mutant PLCε or inhibitor × 100, e.g.
Paired or unpaired Student's t tests were performed where appropriate. A value of P < 0.05 was considered significant.
RESULTS
RTK and GPCR agonists stimulate PLCε
Because we have previously demonstrated that PLCε is activated by Ras [3] , we determined whether RTK agonists that activate Ras stimulate PLCε. The data illustrated in Figure 1 demonstrate that EGF modestly stimulates PLCε overexpressed in COS-7 cells. FBS also stimulated PLCε (Figure 1 ). This stimulation was significantly 4-5-fold greater than EGF even at 1 % FBS. Boiling the serum or using calf or horse serum did not significantly affect the stimulation (results not shown), indicating the response was not due to protein growth factors. In addition, inhibition by RA2 domain point mutants was different from EGF and Q61L H-Ras, suggesting a distinct mechanism of activation (discussed below, Figure 3A ).
Serum contains significant amounts of the LPA (1-10 µM) and S1P (500 nM), so we tested whether LPA or S1P would stimulate PLCε. Figure 1 shows the effect of various hormones including LPA, S1P and thrombin on total inositol phosphate accumulation in the presence or absence of overexpressed PLCε. LPA effectively stimulated inositol phosphate accumulation in the presence of PLCε with an EC 50 of 3 µM, within the range 1-100 µM used to study its effects in other tissues [18] . Similarly, S1P also stimulated PLCε. The K d for S1P receptors is in the low nanomolar range [14] . The EC 50 for S1P in our studies was 100 nM, but S1P at concentrations as low as 10 nM stimulated PLCε consistent with a receptor-mediated activation. Thrombin also stimulated and at very low concentrations with an EC 50 of 30 pM, consistent with activation of a PAR-1 receptor [15] previously characterized in COS-7 cells [19] .
Relative activation of PLCε and other isoforms of PLC
EGF is known to activate PLCγ 1 and LPA, S1P and thrombin have been postulated to activate PLCβ isoforms through G q -and G i -family G-proteins. We compared the efficacy of these agonists to activate PLCε and other PLC isoforms overexpressed in COS-7 cells. EGF modestly stimulated PLCε and PLCγ 1 to similar levels, 1.5-2-fold ( Figure 2A ). In an attempt to enhance this stimulation, EGFR was co-transfected with PLCε or PLCγ 1; however, EGFR had disparate effects on the two PLC isoforms. EGFR markedly potentiated the response to EGF in cells expressing PLCγ 1 in the absence or presence of EGF. In contrast, EGFR alone slightly inhibited basal PLCε activity and only modestly potentiated the effect of EGF.
To determine if Ras limits the EGF stimulation, cells were cotransfected with wild-type H-Ras and PLCε. Unexpectedly, we found that serum, LPA, S1P and thrombin activated transfected PLCε more effectively than PLCβ1 or PLCβ2 isoforms overexpressed in COS-7 cells ( Figure 2E ). FBS and LPA, but not S1P or thrombin, slightly stimulated PLCβ2, but significant stimulation of PLCβ1 by these agonists was not observed. This difference was not due to lack of expression ( Figure 2F ) or ability to activate the enzymes since AlF 4 − effectively stimulated all three isoforms. Furthermore, wild-type Gα q selectively activated overexpressed PLCβ1, but did not potentiate the activation of PLCβ1 by these agonists, indicating that G q is not limiting (G. G. Kelley, unpublished work). It is important to emphasize, however, that these are overexpression studies and should not be interpreted to indicate that these GPCR agonists preferentially couple to endogenous PLCε. Further studies are required in this regard. What they do demonstrate, though, is that signals generated by these agonists in COS-7 cells selectively activate PLCε.
Distinct dependence on the RA2 domain for RTK and GPCR agonist stimulation of PLCε
We previously demonstrated that specific point mutations in the RA2 domain of PLCε inhibit Ras binding and Q61L H-Ras activation of PLC in parallel [3] . Two mutants were particularly instructive: K2150A, which partially inhibited the response to Q61L H-Ras by approx. 50 %, and K2150E, which almost completely inhibited the response [3] . These mutations inhibited the basal activity of PLCε by about 50 %, from (8.17 + − 0.98) × 10 Our previous studies examining the effects of Q61L H-Ras on activation of PLCε using these and additional RA2 domain mutants showed a direct parallel between mutationally induced decreases in Q61L H-Ras binding and activation of PLCε [3] . We therefore utilized these mutants to determine whether EGF, FBS, LPA, S1P and thrombin were inhibited in the same manner as Q61L H-Ras. Similar to our previous studies [3] , activation of K2150A PLCε by Q61L H-Ras was 50 % lower than for wild-type while K2150E PLCε was 90 % lower ( Figure 3A , lower panel). Stimulation of both PLCε mutants by FBS, on the other hand, was 50 % lower than for wild-type ( Figure 3A , upper panel). We therefore compared the effect of these PLCε mutations on its ability to be activated by EGF, LPA, S1P and thrombin. Figure 3(B) shows the stimulation of each PLCε mutant relative to wild-type PLCε (see the Experimental section for calculation details). EGF-dependent PLCε activation was inhibited by these point mutations in the RA2 domain, 90 % by the K2150A mutation and completely by the K2150E mutation, demonstrating a complete dependence on the RA2 domain. Like FBS, however, LPA-, S1P-and thrombin-dependent PLCε activation were only inhibited by approx. 50 % and equally by both mutations (K2150A = K2150E). Thus while EGF stimulation of PLCε was completely dependent on the RA2 domain, FBS, LPA, S1P and thrombin stimulation were only partially dependent.
Ras, Rho and G 12 family G-proteins stimulate PLCε by RA2-dependent and -independent mechanisms
Because the profile of inhibition of agonist stimulation of PLCε by the RA2 mutations was distinct from Q61L H-Ras, other constitutively active G-proteins in the Ras, Rho and G 12 families were screened for their ability to activate PLCε. The data in show that, in addition to Q61L H-Ras, Ras family members Q72L TC21, Q63E Rap1A, Q63E Rap2A, Q63E Rap2B and G23V RalA, Rho family members G14V RhoA and G12V Rac, and G 12 family members Q229L G α12 and Q226L G α13 stimulated PLC activity of transfected PLCε. For comparison purposes, the stimulation is also presented as fold basal PLCε activity (see the Experimental section for calculation details; Figure 4B ). The effect of these G-proteins was not mediated by an increase in the expression of PLCε (see Figure 5C ). Stimulation by the Rap G-proteins was sensitive to the overexpressed protein level and only at low expression levels did they stimulate PLCε (results not shown). Q229L G α12 and Q226L G α13 inhibited PLCε expression but this inhibition was decreased by reducing the amount of plasmid used (results not shown). G12V CDC42 was also examined and stimulation of PLCε was not observed but this G-protein also inhibited PLCε expression. We next determined whether these G-proteins that stimulate PLCε were inhibited by mutations in the RA2 domain in a similar pattern to the various agonists ( Figure 5A ). The effect of the RA2 domain point mutations on the constitutively active G-protein stimulation of PLCε could be broadly divided into two groups. The Ras family G-proteins TC21, Rap1A, Rap2B and Rap2A displayed a similar profile to H-Ras, with the activation of K2150A PLCε > K2150E PLCε, and the K2150E PLCε mutant almost completely resistant to stimulation. A second group of G-proteins was identified whose ability to activate PLCε was unaffected by RA2 domain point mutations. These included Ral, Rho, Rac, G α12 and G α13 . The lack of effect of these mutations on the stimulation of PLCε by these G-proteins was not due to a distinct molecular interaction with the RA2 domain independent of the K2150 residue because deleting the RA2 domain yielded similar results (results not shown).
To correlate activation of PLCε with binding to the RA2 domain, a GST pull-down assay was performed ( Figure 5B ). Consistent with their RA2-dependent activation of PLCε, active TC21, Rap1A, Rap2A and Rap2B bound to the RA2 domain of PLCε and was precipitated with a GST-RA2 fusion protein. Furthermore, inhibition of PLC activation paralleled inhibition of binding to the RA2 domain mutants. The binding of these G-proteins was also GTP-dependent. Constitutively active, GTPbound TC21 and Rap1A bound to a greater degree than their respective wild-type proteins, which are only partially GTP-bound under basal conditions. Constitutively active and wild-type Rap2A and Rap2B bound equally well, consistent with reports of high basal activation of Rap2 [20] ; however, dominant-negative mutants showed no binding (results not shown). We also found that Rap1B (results not shown) and Rap1A ( Figure 5B ) bound to the RA1 domain in a GTP-independent manner, which may be responsible for the relatively low stimulatory effects of Rap1 [21, 22] . 
Effects of FBS, LPA, S1P and thrombin are partially mediated by the G 12 family of heterotrimeric G-proteins
Because LPA, S1P and thrombin couple to the G 12 family of heterotrimeric G-proteins, which are endogenously expressed in COS-7 cells (results not shown), and the profile of inhibition of Q229L G α12 and Q226L G α13 by the RA2 mutants was similar, we determined whether G α12 /G α13 mediated the response of these agonists. The RGS domain of p115RhoGEF binds and activates the GTPase activity of G α12 and G α13 and has been used to inhibit signalling pathways mediated by these G-proteins [23] .
Figures 6(A) and 6(B) show that co-expression of the RGS domain with PLCε markedly inhibited LPA, S1P and thrombin stimulation of PLCε in a dose-dependent manner. In contrast to its effects on these agonists, the RGS domain had no effect on the ability of EGF, Q61L H-Ras or Q229L G α12 to stimulate PLCε ( Figure 6B ). It is likely that the RGS domain did not inhibit Q229L G α12 because of the relatively high level of overexpression of the G α12 subunit and its inability to stimulate the GTPase activity of the mutant.
We next determined whether wild-type G α12 or G α13 would potentiate the stimulatory effects of LPA, S1P and thrombin on PLCε. Wild-type G α12 potentiated the response to LPA and thrombin but not S1P or EGF ( Figure 6D ). Attempts were made to determine whether wild-type G α13 also potentiated the response to these agonists and in particular S1P; however, even at low levels, wild-type G α13 inhibited expression of PLCε by greater than 70 % (see Figure 6E) . In contrast to the synergy observed with G α12 , wild-type H-Ras did not potentiate LPA, S1P or thrombin (Figure 6D ).
LPA and S1P stimulation are partially sensitive to pertussis toxin
Because Gβ and Gγ subunits co-expressed with PLCε stimulate PLCε [8] and LPA, S1P and thrombin also couple to the G i /G o family of G-proteins, we determined whether part of the stimulation of FBS, LPA, S1P or thrombin is mediated by activation of G i (G i but not G o is expressed in COS-7 cells [24] ). Pertussis toxin inhibits G i activation and Gβγ release by ADP-ribosylating Gα i . Pre-incubation with pertussis toxin, 100 µg/ml overnight, had no effect on PLCε expression or basal PLCε activity but modestly inhibited LPA (3 µM; 35 + − 5 %, P < 0.01; n = 4) and S1P (300 nM; 31 + − 4 %, P < 0.02; n = 4) stimulation of PLCε. In contrast, pertussis toxin did not inhibit thrombin (300 pM) or EGF (20 ng/ml). Since Gα i does not stimulate PLCε [4] , these studies are consistent with Gβγ mediating at least part of the effects of LPA and S1P on PLCε. 
RA2-dependent stimulation of LPA, S1P and thrombin
The partial inhibition of serum, LPA, S1P and thrombin stimulation of PLCε by RA2 domain point mutations suggests that stimulation by these agonists is a composite of RA2-dependent and -independent inputs. LPA, S1P and thrombin have also been shown to transactivate the EGFR [16, 17, 19] , which would be expected to generate an RA2-dependent signal similar to EGF. Figure 7 (A) shows that AG1478, a specific EGFR kinase inhibitor, potently inhibited EGF and EGF + wild-type Ras. AG1478, however, only slightly inhibited LPA-stimulated activity by 10 % [(7.35 + − 0.56) × 10 −3 to (6.60 + − 0.53) × 10 −3 c.p.m., P < 0.02; n = 5] and had no significant effect on S1P or thrombin-stimulated PLC activity, indicating that EGFR transactivation does not have a major role in the stimulation of PLCε by these agonists in COS-7 cells.
Ras and Rap GEFs are also activated by second messengers, Ca 2+ and diacylglycerol, generated from stimulation of PLC [16, 25] . We therefore utilized dominant-negative S17N H-Ras, which inhibits Ras-dependent pathways by preventing GEFs from exchanging GDP with GTP, and RapGAP1, a GTPase-activating protein for Rap1 and to a lesser extent Rap2 [26] . Dominantnegative Ras significantly inhibited EGF and EGF + wild-type H-Ras by 43 and 93 % respectively but had no significant effect on LPA, S1P or thrombin stimulation of PLCε ( Figure 7B ). RapGAP1, on the other hand, significantly inhibited activation of PLCε by all agonists ( Figure 7C ). LPA, S1P and thrombin activation of PLCε were inhibited by approx. 30 % and EGF was inhibited by 54 %, suggesting that Rap mediates at least part of the RA2-dependent stimulation by these agonists.
EGF, LPA, S1P or thrombin do not interact synergistically to stimulate PLCε
Because EGF activates PLCε by a distinct pathway from LPA, S1P or thrombin, we determined whether these agonists would interact synergistically to stimulate PLCε. Table 1 lists the fold stimulation above PLCε control for each agonist alone and in combination and 1-1 µM) , added 10 min prior to start of the experiment and then FBS (10 %), LPA (3 µM), S1P (300 nM), thrombin (300 pM) or EGF (20 ng/ml) was added (n = 3-4). *P at least < 0.05 compared with control. Basal PLCε activity: PLCε, (5.54 + − 1.35) × 10 −3 ; PLCε + AG1478, (5.37 + − 1.16) × 10 −3 c.p.m.; P = not significant; n = 5. (B) Effect of dominant-negative S17N H-Ras on agonist-stimulated PLC activity. COS-7 cells were transiently transfected as in A except S17N H-Ras (125 ng/well) and/or wild-type H-Ras (125 ng/well) or LacZ was used as the second plasmid and PLC activity was determined as indicated (n = 4-6). *P at least < 0.01 compared with control. Basal PLCε activity: PLCε, (3.34 + − 1.22) × 10 −3 ; PLCε + S17N H-Ras, (2.96 + − 1.22) × 10 −3 c.p.m.; P = not significant, n = 6. (C) Effect of RapGAP1 on agonist-stimulated PLC activity. COS-7 cells were transiently transfected as in B except RapGAP1 (25 ng/well) or LacZ was used as the second plasmid and PLC activity was determined as indicated (n = 4-6). *P at least < 0.05 compared with control; + P at least < 0.05 compared with EGF + wild-type H-Ras and thrombin. Basal PLCε activity: PLCε, (1. 
Table 1 Hormonal and GTPase interactions
COS-7 cells were transfected with PLCε or LacZ and with vector, Q61L H-Ras and/or Q229L G α12 (30 ng/well) as indicated. Cells were stimulated with LPA (3 µM), S1P (300 nM), thrombin (300 pM) and/or EGF (20 ng/ml) and total inositol phosphates were measured. Values are fold stimulation above control and are means + − S.E.M. from the indicated number of experiments performed (n) in duplicate. First and second refer to the agents listed under condition. Combined is the value obtained in the presence of both agents. The expected value by adding the response to both stimulators is given in parentheses in the combined column. P shows the P value comparing the observed combined value with the expected calculated value; NS, not significant. LPA, S1P and thrombin also stimulated PLCε through endogenous receptors. This stimulation was greater than for EGF, although, in the presence of wild-type H-Ras the stimulation of PLCε by EGF approached the levels observed with these agonists. Serum also stimulated PLCε, probably through high concentrations of LPA and S1P in serum. Unlike EGF, however, mutations in the RA2 domain only partially inhibited the stimulatory effects of these agonists, indicating a distinct RA2-independent mechanism of activation. In an attempt to elucidate this pathway we identified a group of G-proteins that stimulate PLCε in a predominantly RA2-independent manner, determined by stimulation of RA2 domain point mutants, which included G α12 , G α13 , RalA, RhoA and Rac. The mechanism by which these G-proteins stimulate PLCε is not known; however, several lines of evidence presented here suggest that endogenous receptor activation of G α12 and/or G α13 functionally mediates the stimulation of PLCε by LPA, S1P and thrombin in COS-7 cells. First, the profile of inhibition by mutations in the RA2 domain was similar; secondly, the RGS domain of p115RhoGEF, which binds and inactivates G α12 and G α13 [23] , inhibited the stimulation of PLCε; and thirdly, wild-type G α12 potentiated the stimulation of PLCε induced by LPA and thrombin.
G α12 and G α13 are known to activate Rho by stimulating the exchange activity of Rho GEFs [28] , and both G α12 and G α13 have been shown to stimulate Rho in COS-7 cells [29] . Thus, it is possible that the stimulatory effects of these G-proteins are mediated through activation of Rho, which we have demonstrated stimulates PLCε in an RA2-independent manner similar to G α12 and G α13 . On the other hand, we also observed differences in the stimulation of PLCε by active G α12 , G α13 and RhoA. This was particularly apparent for Q229L G α12 , which stimulated PLCε more than Q226L G α13 , and was more dependent on the RA2 domain than either Q226L G α13 or G14V RhoA. Thus, while it is likely that part of the stimulatory response to G α12 and G α13 is mediated by Rho, a component may be Rho-independent.
We also found that the effects of LPA and S1P, but not thrombin, were partially sensitive to pertussis toxin. This suggests that these agonists stimulate PLCε through activation of G i and probably through Gβγ since Gα i does not stimulate PLCε [4] . Interestingly, a similar differential sensitivity of LPA and thrombin to pertussis toxin has been noted previously in COS-7 cells for transactivation of the EGFR [19] . The mechanism by which Gβγ stimulates PLCε is not known, but it is RA2-independent [8] and appears distinct from its regulation of PLCβ isoforms because purified Gβγ failed to stimulate PLCε but markedly stimulated PLCβ2 in an in vitro reconstitution assay [3] .
In addition to the RA2-independent stimulation, our studies also suggest that a component of the LPA, S1P and thrombin stimulation of PLCε is dependent on an intact RA2 domain. Whether these GPCR agonists stimulate a G-protein that binds to the RA2 domain, or simply require a G-protein to be bound to the domain to activate the enzyme, remains to be determined. However, these agonists have been shown to activate Ras or Rap GEFs by mechanisms involving transactivation of RTKs, Ca 2+ / calmodulin or Ca 2+ /diacylglycerol [25, 30] . While many studies have shown that LPA and thrombin activate the Ras/mitogen-activated protein kinase pathway in COS-7 cells through transactivation of the EGFR [19, 31, 32] , we found that AG1478 inhibited the LPA response by only 10 % and had no effect on S1P or thrombin stimulation under conditions where the EGF stimulation was completely inhibited. Furthermore, wild-type H-Ras potentiated the stimulatory response to EGF but not to LPA, S1P or thrombin and dominant negative S17N H-Ras did not significantly inhibit the stimulation. On the other hand RapGAP1 inhibited the stimulation by these GPCR agonists, suggesting a role for Rap. Since Ca 2+ and diacylglycerol activate certain Rap GEFs [16, 19, 25] , a parallel activation of another PLC isoform or stimulation of PLCε by these agonists could activate Rap. The CDC25 domain has been reported to be a Rap1A GEF [33] and we have made similar observations (A. V. Smrcka and G. G. Kelley, unpublished work). Thus, another intriguing possibility is that this domain mediates part of the Rap-and RA2-dependent activation of PLCε by these agonists.
Our studies demonstrate that LPA, S1P, thrombin and EGF couple to PLCε in COS-7 cells. While differential coupling of these receptors to PLCε and other PLC isoforms will require studies manipulating endogenous isoforms in multiple cell lines, these findings are significant because they raise the possibility that PLCε may regulate critical cellular functions previously thought to be mediated by other PLC isoforms [1, 2] . Furthermore, given the diverse regulation of PLCε, it is likely that other pathways will be identified that regulate PLCε. In this regard, β2-adrenergic, M 3 muscarinic and prostaglandin E 1 receptor-mediated activation of cAMP has been shown to stimulate PLCε through activation of the Rap GEF, Epac1 and Rap2B [34, 35] .
In summary, our studies demonstrate diverse hormonal regulation of PLCε. Activation of a RTK by EGF stimulates PLCε in an RA2-dependent manner mediated by Ras and Rap. In contrast, activation of GPCRs by LPA, S1P and thrombin stimulate PLCε in an RA2-independent manner mediated by G 12 /G 13 and G i and in an RA2-dependent manner through Rap. The mechanism by which G-proteins, G α12 /G α13 , Rho, Rac and Ral, stimulate PLCε in an RA2-dependent manner remains to be determined.
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